Market Intelligence, Clinical Progress, and High-Purity Reagents for Epitranscriptomics and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for WTAP drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WTAP Recombinant Protein (Full-Length / Truncated) High purity (>95%), Endotoxin controlled. Sequence Verified for PPI assays. |
View WTAP Products |
| Gene Delivery | WTAP Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and rescue assays. |
View WTAP Products |
| Benchmark Ab | Anti-WTAP Recombinant Antibody High-affinity positive control for immunoprecipitation (IP) and Western Blot. |
View WTAP Products |
| Validator | WTAP siRNA Set Target-specific knockdown verification in cancer cell lines. |
View WTAP Products |
| Related Target A | METTL3 Core catalytic component of the m6A methyltransferase complex; interacts directly with WTAP. |
View METTL3 Products |
| Related Target B | METTL14 Structural support partner in the m6A writer complex, forming a heterodimer with METTL3. |
View METTL14 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro WTAP-METTL3/14 interaction reconstitution | Tag-optimized recombinant WTAP and METTL3/14 complex proteins available with >95% purity. |
| Off-target screening against other splicing factors | Homolog and splicing-associated protein panels strictly verified by mass spectrometry. |
| Lack of Controls | Sequence-verified validation antibodies and control plasmids included. |
| False Positives in RNA Methylation Assays | Validated siRNA sets included for cellular target specificity verification. |
Live WTAP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for WTAP therapeutics is intensifying, with major players shifting focus from traditional epitranscriptomic pathways to targeted protein degradation (PROTACs) and small molecule protein-protein interaction (PPI) inhibitors. As first-generation epitranscriptomic therapies reach the clinic, the next wave of R&D is targeting the WTAP-METTL3-METTL14 complex interface to selectively disrupt m6A writer machinery in myeloid leukemias and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI | Academic/Biotech Consortia | Acute Myeloid Leukemia (AML) | Disruption assays (Need high-purity WTAP and METTL3/14 proteins) |
| PROTAC / Degrader | Epitranscriptomic-focused Biopharma | Solid Tumors (HCC, Glioblastoma) | Ubiquitination & ternary complex assays (Need tagged WTAP) |
| RNAi / Antisense | RNA Therapeutics Specialists | Advanced Refractory Cancers | In vitro knockdown validation (Need verified siRNA/Lentivirus) |